Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Debt Repayments (2017 - 2025)

Northwest Biotherapeutics (NWBO) has 14 years of Long-Term Debt Repayments data on record, last reported at -$277000.0 in Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments fell 150.27% year-over-year to -$277000.0; the TTM value through Sep 2025 reached $569000.0, down 31.86%, while the annual FY2024 figure was $1.1 million, 188.31% up from the prior year.
  • Long-Term Debt Repayments reached -$277000.0 in Q3 2025 per NWBO's latest filing, down from $536000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $4.0 million in Q1 2022 and bottomed at -$277000.0 in Q3 2025.
  • Average Long-Term Debt Repayments over 5 years is $856214.3, with a median of $242500.0 recorded in 2023.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 27450.0% in 2024, then plummeted 150.27% in 2025.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $3.8 million in 2021, then tumbled by 97.41% to $99000.0 in 2022, then surged by 76.77% to $175000.0 in 2023, then skyrocketed by 77.14% to $310000.0 in 2024, then crashed by 189.35% to -$277000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were -$277000.0 in Q3 2025, $536000.0 in Q1 2025, and $310000.0 in Q4 2024.